dapagliflozin治疗射血分数降低的心力衰竭的最新进展

Q4 Medicine
Carlos Escobar , Manuel Anguita , Vivencio Barrios , José María Fernández Rodríguez , José María García Pinilla , José González-Costello , Álvaro González Franco , Ricardo Gómez Huelgas
{"title":"dapagliflozin治疗射血分数降低的心力衰竭的最新进展","authors":"Carlos Escobar ,&nbsp;Manuel Anguita ,&nbsp;Vivencio Barrios ,&nbsp;José María Fernández Rodríguez ,&nbsp;José María García Pinilla ,&nbsp;José González-Costello ,&nbsp;Álvaro González Franco ,&nbsp;Ricardo Gómez Huelgas","doi":"10.1016/S1131-3587(21)00004-2","DOIUrl":null,"url":null,"abstract":"<div><p>Despite progress in the treatment of heart failure with reduced ejection fraction (HFrEF), mortality and hospitalization rates remain very high. The DAPA-HF trial demonstrated that, compared with standard treatment, the addition of dapagliflozin, 10 mg/day, was associated with marked clinical benefits in patients with HFrEF. Significant reductions were observed in several outcomes: (i) a 26% reducción in the risk of cardiovascular death, hospitalization or an emergency department visit for heart failure that resulted in intravenous treatment; (ii) a 30% reduccion in the risk of a first hospitalization for heart failure; (iii) an 18% reduccion in cardiovascular mortality; and (iv) a 17% reduccion in all-cause mortality. In addition, the adverse event rate was low. These beneficial effects were independent of the presence of diabetes. Moreover, it was found that the earlier treatment with dapagliflozin was started, the greater the benefit, irrespective of the patient’s existing treatment for heart failure. This article provides an update on dapagliflozin treatment for patients with HFrEF and presents recommendations on the drug’s use in practice.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Puesta al día sobre el empleo de dapagliflozina en insuficiencia cardiaca con fracción de eyección reducida\",\"authors\":\"Carlos Escobar ,&nbsp;Manuel Anguita ,&nbsp;Vivencio Barrios ,&nbsp;José María Fernández Rodríguez ,&nbsp;José María García Pinilla ,&nbsp;José González-Costello ,&nbsp;Álvaro González Franco ,&nbsp;Ricardo Gómez Huelgas\",\"doi\":\"10.1016/S1131-3587(21)00004-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Despite progress in the treatment of heart failure with reduced ejection fraction (HFrEF), mortality and hospitalization rates remain very high. The DAPA-HF trial demonstrated that, compared with standard treatment, the addition of dapagliflozin, 10 mg/day, was associated with marked clinical benefits in patients with HFrEF. Significant reductions were observed in several outcomes: (i) a 26% reducción in the risk of cardiovascular death, hospitalization or an emergency department visit for heart failure that resulted in intravenous treatment; (ii) a 30% reduccion in the risk of a first hospitalization for heart failure; (iii) an 18% reduccion in cardiovascular mortality; and (iv) a 17% reduccion in all-cause mortality. In addition, the adverse event rate was low. These beneficial effects were independent of the presence of diabetes. Moreover, it was found that the earlier treatment with dapagliflozin was started, the greater the benefit, irrespective of the patient’s existing treatment for heart failure. This article provides an update on dapagliflozin treatment for patients with HFrEF and presents recommendations on the drug’s use in practice.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358721000042\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358721000042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

尽管在治疗心力衰竭伴射血分数降低(HFrEF)方面取得了进展,但死亡率和住院率仍然很高。DAPA-HF试验表明,与标准治疗相比,添加10mg /天的达格列净与HFrEF患者的显着临床益处相关。在几个结果中观察到显著降低:(i)心血管死亡、因心力衰竭住院或急诊就诊导致静脉注射治疗的风险降低26% reducción;(ii)首次因心力衰竭住院的风险降低30%;(三)心血管疾病死亡率降低18%;(四)全因死亡率降低17%。此外,不良事件发生率低。这些有益的影响与糖尿病的存在无关。此外,研究发现,无论患者现有的心力衰竭治疗方法如何,越早开始使用达格列净治疗,获益越大。本文提供了关于达格列净治疗HFrEF患者的最新情况,并提出了该药物在实践中的使用建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Puesta al día sobre el empleo de dapagliflozina en insuficiencia cardiaca con fracción de eyección reducida

Despite progress in the treatment of heart failure with reduced ejection fraction (HFrEF), mortality and hospitalization rates remain very high. The DAPA-HF trial demonstrated that, compared with standard treatment, the addition of dapagliflozin, 10 mg/day, was associated with marked clinical benefits in patients with HFrEF. Significant reductions were observed in several outcomes: (i) a 26% reducción in the risk of cardiovascular death, hospitalization or an emergency department visit for heart failure that resulted in intravenous treatment; (ii) a 30% reduccion in the risk of a first hospitalization for heart failure; (iii) an 18% reduccion in cardiovascular mortality; and (iv) a 17% reduccion in all-cause mortality. In addition, the adverse event rate was low. These beneficial effects were independent of the presence of diabetes. Moreover, it was found that the earlier treatment with dapagliflozin was started, the greater the benefit, irrespective of the patient’s existing treatment for heart failure. This article provides an update on dapagliflozin treatment for patients with HFrEF and presents recommendations on the drug’s use in practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信